Trial Information

Summary: Age-Related Changes in Nanoparticle Albumin Bound (nab) Paclitaxel Pharmacokinetics and Pharmacodynamics

You have been asked to participate in this research study because you have breast cancer that has spread to other parts of your body and you are going to receive treatment with the drug, nab-paclitaxel. This is called a pharmacokinetics (PK) and pharmacodynamics (PD) study. The purpose of PK and PD is to measure levels of nab-paclitaxel in blood samples taken at different times after the drug is given to determine if age is associated with a change in the amount of nab-paclitaxel in the body or the side effects it causes. Your treatment on this study is expected to last as long as your disease does not worsen and you do not have unmanageable side effects. After your treatment on this study is over, your medical condition will continue to be followed for 30 days or until all side effects have resolved to levels at the start of study.

Patient Inclusion/Exclusion Criteria:

- See http://clinicaltrials.coh.org for additional information.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: July 7, 2008 at 3:20:35 PM